contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


crna-circio-selected-for-oral-presentation-at-esgct-2024-annual-meeting

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Targovax

· Circio has been selected to present its circVec circular RNA expression platform at the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2024, taking place on 22-25 October...

<pre>· Circio has been selected to present its circVec circular RNA expression platform at the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2024, taking place on 22-25 October 2024 in Rome, Italy · ESGCT is one of the most prestigious and widely attended international conferences in the gene therapy field · In the presentation, Circio wil showcase the latest developments and in vivo data for its circVec circular RNA expression platform designed to enhance gene therapy Oslo, Norway 24 September 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology company developing next generation circular RNA vector technology for gene therapy, today announces that a scientific abstract submitted to the European Society of Cell and Gene Therapy (ESGCT) annual meeting 2024 has been selected for oral presentation. The presentation will be given by CircioŽs CTO, Dr. Thomas B Hansen on 23 October 2024. "CircioŽs unique and powerful circVec platform keeps building momentum, and we are very excited to be selected to present our technology at the prestigious ESGCT meeting." said Dr. Thomas B. Hansen, CTO of Circio &nbsp;"This meeting provides a great opportunity to showcase how the latest circVec generation continues to significantly outperform mRNA-based expression, thereby delivering a substantial improvement over current gold-standard gene therapy approaches." The ESGCT invitation follows recent presentations at several RNA industry conferences and coverage in international life science media, highlighting the advantages and potential of circular RNA therapeutics and reinforcing CircioŽs position as a leader in this rapidly emerging field. Title of presentation: Optimization of in vitro and in vivo performance of circVec, a vector-based circular RNA expression platform for enhanced gene therapy Presenter: Dr. Thomas B Hansen, CTO Time and location: 23 October 2024 @ 19:30hrs CET - Rome, Italy For further information, please contact: Erik Digman Wiklund, CEO Phone: +47 413 33 536 Email: erik.wiklund@circio.com About Circio Building next generation RNA therapeutics Circio Holding ASA is a biotechnology company developing novel circular RNA and immunotherapy medicines. Circio has established a unique circular RNA (circRNA) platform for genetic medicine. The proprietary circVec technology is based on a modular genetic cassette design for efficient biogenesis of multifunctional circRNA from DNA and viral vectors, which can be deployed in multiple disease settings. The circVec platform has demonstrated enhanced and more durable protein expression than classic mRNA vector systems, and has the potential to become the new gold -standard for DNA and virus-based therapeutics in the future. The circRNA R&amp;D activities are being conducted by the wholly owned subsidiary Circio AB based at the Karolinska Institute in Stockholm, Sweden. </pre>

CRNA: Circio selected for oral presentation at ESGCT 2024 annual meeting

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

What does negative working capital mean and why is it a good thing?

Income statement

Amazon and Costco in Sweden: A looming threat that Nordic retailers ignore at their peril

Stay up to date with our newsletter